The CCDC9 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited heterogeneous population of HeLa human cervical adenocarcinoma epithelial cells carrying targeted disruptions in the CCDC9 gene. This polyclonal format, derived from Cas9-mediated gene editing and selection, ensures a high frequency of CCDC9 null cells while retaining natural genetic variability. The product serves as a versatile loss-of-function model for studying CCDC9’s role in centrosome organization and mitotic regulation within a cancer-relevant human cell context.
HeLa cells are an immortalized human epithelial cell line isolated from a cervical adenocarcinoma and are positive for human papillomavirus type 18 (HPV18), which leads to inactivation of the p53 and pRb tumor suppressors. This genetic background promotes robust, uncontrolled proliferation and has established HeLa as a workhorse in cancer biology and cell cycle research. The CCDC9 knockout in this context allows investigation of centrosome-related phenotypes in cells with inherent checkpoint deficiencies.
CCDC9 encodes a centrosomal coiled-coil domain protein critical for mitotic spindle assembly. It functions downstream of mitotic kinases CDK1, PLK1, and Aurora A, which phosphorylate CCDC9 to regulate its activity. The protein interacts with CEP135, CEP250, and the dynein motor complex to promote recruitment of ??-tubulin and assembly of the ??-tubulin ring complex. Additionally, CCDC9 participates in centriole duplication and ciliogenesis. Loss of CCDC9 disrupts these processes, leading to multipolar spindles, chromosome missegregation, and cell cycle arrest.
In the HeLa cell environment, CCDC9 knockout reveals a heightened dependency on centrosome integrity for error-free mitosis. The existing HPV18-mediated checkpoint defects sensitize cells to centrosome dysfunction, resulting in pronounced mitotic delays, aneuploidy, and increased apoptosis. The polyclonal nature of the model captures a range of phenotypic severities, making it valuable for studying the heterogeneity of centrosome vulnerability in cancer. Furthermore, it provides a platform to explore synthetic lethal strategies where CCDC9 loss enhances sensitivity to mitotic kinase inhibitors or chemotherapeutics.
This knockout model supports diverse functional assays: immunofluorescence for centrosomal markers (??-tubulin, pericentrin) to assess spindle integrity; Western blotting for cyclin B, phospho-histone H3, and CDK1; and propidium iodide-based flow cytometry for cell cycle analysis. Live-cell imaging enables real-time visualization of mitotic progression. Additionally, colony formation assays, Annexin V apoptosis detection, and RT-qPCR for ciliogenesis-related transcripts can be performed. These cells are thus suited for centrosome biology, cancer cell proliferation studies, drug sensitivity screening, and ciliopathy research. For technical details, please contact Ascent Research.
